信達生物(01801.HK)與勁方醫藥就候選藥物達獨家全球戰略合作
信達生物(01801.HK)公佈,公司與勁方醫藥(一家開發腫瘤和免疫領域的領先療法的臨牀階段生物技術公司)達成全球獨家授權協議,公司將作爲獨家合作夥伴獲得勁方醫藥候選藥物GFH925(KRAS G12C抑制劑)在內地、香港、澳門及臺灣的開發和商業化權利,並擁有全球開發和商業化權益的選擇權。
勁方醫藥自主研發的GFH925已獲得國家藥品監督管理局的臨牀試驗批準。臨牀前實驗數據顯示,GFH925擁有潛在同類最佳的活性,可有效抑制多種攜帶KRAS G12C突變的腫瘤細胞系生長,有利於加速臨牀上的有效性驗證。其他臨牀前試驗也展現了與其他療法的聯用潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.